One-year follow-up of clinical convergence measures in children enrolled in the Convergence Insufficiency Treatment Trial-Attention and Reading Trial

Ann M Morrison,Marjean T Kulp,Susan A Cotter,Mitchell M Scheiman,Erin C Jenewein,Tawna L Roberts,G Lynn Mitchell,L Eugene Arnold,Dashaini Retnasothi,Annette Bade,Richard Hertle,Eric Borsting,Convergence Insufficiency Treatment Trial—Attention and Reading (CITT‐ART) Investigator Group,Jeffrey Cooper,Erica Schulman,Kimberly Hamian,Danielle Iacono,Steven Larson,Valerie Leung,Sara Meeder,Elaine Ramos,Steven Ritter,Audra Steiner,Alexandria Stormann,Marilyn Vricella,Xiaoying Zhu,Susanna Tamkins,Naomi Aguilera,Elliot Brafman,Hilda Capo,Kara Cavuoto,Isaura Crespo,Monica Dowling,Kristie Draskovic,Miriam Farag,Vicky Fischer,Sara Grace,Ailen Gutierrez,Carolina Manchola-Orozco,Maria Martinez,Craig McKeown,Carla Osigian,Leslie Small,Natalie Townsend,Michael Gallaway,Mark Boas,Christine Calvert,Tara Franz,Amanda Gerrouge,Donna Hayden,Erin Jenewein,Zachary Margolies,Shivakhaami Meiyeppen,Jenny Myung,Karen Pollack,Mitchell Scheiman,Ruth Shoge,Andrew Tang,Noah Tannen,Lynn Trieu,Luis Trujillo,Marjean Kulp,Michelle Buckland,Allison Ellis,Jennifer Fogt,Catherine McDaniel,Taylor McGann,Ann Morrison,Shane Mulvihill,Adam Peiffer,Maureen Plaumann,Gil Pierce,Julie Preston,Kathleen Reuter,Nancy Stevens,Jake Teeny,Andrew Toole,Douglas Widmer,Aaron Zimmerman,Susan Cotter,Carmen Barnhardt,Angela Chen,Raymond Chu,Kristine Huang,Susan Parker,Dashaini Retnasothie,Judith Wu,Penny Clark,Kelly Culp,Kathy Fraley,Drusilla Grant,Nancy Hanna,Stephanie Knox,William Lawhon,Lan Li,Sarah Mitcheff,Isabel Ricker,Tawna Roberts,Casandra Solis,Palak Wall,Samantha Zaczyk,Kristine Hopkins,Wendy Marsh-Tootle,Michelle Bowen,Terri Call,Kristy Domnanovich,Marcela Frazier,Nicole Guyette,Oakley Hayes,John Houser,Sarah Lee,Jenifer Montejo,Tamara Oechslin,Christian Spain,Candice Turner,Katherine Weise,Rachel Coulter,Deborah Amster,Surbhi Bansal,Laura Falco,Gregory Fecho,Katherine Green,Gabriela Irizarry,Jasleen Jhajj,Nicole Patterson,Jacqueline Rodena,Yin Tea,Julie Tyler,Dana Weiss,Lauren Zakaib,Ingryd Lorenzana,Yesena Meza,Ryan Mann,Mariana Quezada,Scott Rein,Indre Rudaitis,Susan Stepleton,Beata Wajs,Maryann Redford,Carolyn Denton,Eugene Arnold,Christopher Chase,Sharyl Wee,Katlynn Dahl-Leonard,Kenneth Powers,Amber Alaniz,Marie Diener-West,William V Good,David Grisham,Christopher J Kratochvil,Dennis Revicki,Jeanne Wanzek,Mustafa Alrahem,Julianne Dangelo,Jordan Hegedus,Ian Jones,Lisa A Jones-Jordan,Alexander Junglas,Jihyun Lee,Jadin Nettles,Curtis Mitchell,Mawada Osman,Gloria Scott-Tibbs,Loraine Sinnott,Chloe Teasley,Victor Vang,Robin Varghese
DOI: https://doi.org/10.1111/opo.13378
2024-08-14
Abstract:Purpose: To assess the long-term stability of clinical measures of convergence (near point of convergence [NPC] and positive fusional vergence [PFV]) in participants enrolled in the Convergence Insufficiency Treatment Trial-Attention and Reading Trial (CITT-ART) who received 16 weeks of office-based vergence/accommodative therapy. Methods: A total of 310 children, 9-14 years old, with symptomatic convergence insufficiency were enrolled in CITT-ART. Some 270 completed both their 16-week primary outcome visit followed by a 1-year follow-up visit. Of those 270, 181 (67%) were randomised to the vergence/accommodative therapy. Of the 181 in the vergence/accommodative group, 121 (67%) reported not receiving any additional treatment after the 16-week primary outcome visit. The mean change in NPC, PFV and percentages of children classified by the predetermined success criteria of convergence (normal NPC [<6 cm] and/or improved by ≥4 cm; normal PFV [passing Sheard's criterion and base-out break >15Δ] and/or improved by ≥10Δ) were compared at the 16-week primary outcome visit and 1 year later. Results: Of the 121 who returned for their 1-year follow-up visit, there was no significant change in mean adjusted NPC (reduction of -0.2 cm; 95% CI: -1.0 to 0.5 cm) at 1 year. There was a statistically significant decrease in mean-adjusted PFV (-4.7∆; 95% CI: -6.5 to -2.8Δ) at 1 year. There were similar percentages of participants classified as 'normal' (p = 0.30), 'normal and/or improved' (p > 0.50) and 'normal and improved' (p > 0.14) based on NPC and PFV at the 1-year visit compared with the 16-week primary outcome visit. Conclusion: The improvements in NPC and PFV following 16 weeks of vergence/accommodative therapy (with no reported additional treatment thereafter) in children with symptomatic convergence insufficiency persisted 1-year post-treatment.
What problem does this paper attempt to address?